Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TSKF To Enter Consumer Health Sector In China

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline has mapped out its global strategy to increase investment in the consumer healthcare sector. In line with the direction, GSK's China joint venture TSKF marketed its first dental health product Sensodyne toothpaste in the country late 2008 (PharmAsia News, Oct. 13, 2008). TSKF said that the move represented a strategic expansion from merely an OTC business to consumer health; focus and investment in the core OTC market will continue. The company recently launched a new headache package for its top OTC earner Fenbid to extend the brand. Capturing a quarter of China's analgesics market, Fenbid contributed RMB 500 million ($73 million) to TSKF's total revenue of RMB 1.6 billion in 2008. (Click here for more - Chinese language)

You may also be interested in...

GSK's China Venture Enters Health Products Sector

Tianjin Smith Kline & French Lab, which has been focusing on the OTC business for 21 years in China, marked its entry into the country's healthcare product business last month by launching parent company GlaxoSmithKline's Sensodyne toothpaste. GSK's oral health and health food sectors contribute 27 percent each to its total revenue. As the pharmaceutical giant's China joint venture, TSKF will fully operate the local consumer health business and introduce other items including health food in the near feature. TSKF notes that with the domestic market emerging, the time is right to promote such products. However, it will still concentrate on the OTC business during the next five years even as it increases investments in other sectors. (Click here for more - Chinese Language)

HBW Executive Decisions: HELP Endorses Hahn, Industry Award For AHPA's McGuffin, CHPA, Herbalife Hires

CHPA adds Allgaier to head development, relations; Vetere joins Herbalife as VP, CIO; Hahn's FDA commissioner nomination clears HELP committee; and AHPA's McGuffin recognized as 2019 Industry Leader.

Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts